Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses

• Published in: mBio Vol. 15; no. 1; p. e0177523
• Main Authors: Wan, Jiawu, Wang, Zongmei, Wang, Lingli, Wu, Liqin, Zhang, Chengguang, Zhou, Ming, Fu, Zhen F, Zhao, Ling
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 16-01-2024
• Subjects: CircRNA vaccine; humoral immunity; long-term protection; lymph node-targeting delivery; lyophilization; Research Article; Vaccines; long-term protection; lymph node-targeting delivery; humoral immunity; lyophilization; CircRNA vaccine
• ISSN: 2150-7511; 2150-7511
• DOI: 10.1128/mbio.01775-23

messenger RNA (mRNA) vaccines are a key technology in combating existing and emerging infectious diseases. However, the inherent instability of mRNA and the nonspecificity of lipid nanoparticle-encapsulated (LNP) delivery systems result in the need for cold storage and a relatively short-duration immune response to mRNA vaccines. Herein, we develop a novel vaccine in the form of circRNAs encapsulated in LNPs, and the circular structure of the circRNAs enhances their stability. Lyophilization is considered the most effective method for the long-term preservation of RNA vaccines. However, this process may result in irreversible damage to the nanoparticles, particularly the potential disruption of targeting modifications on LNPs. During the selection of lymph node-targeting ligands, we found that LNPs modified with mannose maintained their physical properties almost unchanged after lyophilization. Additionally, the targeting specificity and immunogenicity remained unaffected. In contrast, even with the addition of cryoprotectants such as sucrose, the physical properties of LNPs were impaired, leading to an obvious decrease in immunogenicity. This may be attributed to the protective role of mannose on the surface of LNPs during lyophilization. Freshly prepared and lyophilized mLNP-circRNA vaccines elicited comparable immune responses in both the rabies virus model and the SARS-CoV-2 model. Our data demonstrated that mLNP-circRNA vaccines elicit robust immune responses while improving stability after lyophilization, with no compromise in tissue targeting specificity. Therefore, mannose-modified LNP-circRNA vaccines represent a promising vaccine design strategy.